Non-Invasive Ventilation (NIV) has become a cornerstone in managing Sleep-Related Breathing Disorders (SRBDs) such as Obstructive Sleep Apnea (OSA) and Central Sleep Apnea (CSA). These conditions are characterized by recurrent upper airway obstruction or impaired respiratory drive during sleep, leading to significant health consequences including cardiovascular complications, metabolic disturbances, and cognitive impairment. This review explores the mechanisms and benefits of various NIV modalities, such as Continuous Positive Airway Pressure (CPAP) and Bi-Level Positive Airway Pressure (BiPAP), in treating SRBDs. CPAP is the gold standard for OSA, effectively reducing Apnea-Hypopnea Index (AHI), improving sleep quality, and decreasing cardiovascular risks. BiPAP offers advantages for patients intolerant to CPAP or with higher pressure requirements. Adaptive Servo-Ventilation (ASV) and Volume-Assured Pressure Support (VAPS) have shown efficacy in managing CSA and hypoventilation syndromes, particularly in neuromuscular disorders and heart failure patients. Despite its effectiveness, adherence to NIV therapy poses a significant challenge due to factors like mask discomfort and noise. Technological advancements in NIV devices, including auto-titrating capabilities and improved comfort features, are crucial for enhancing patient compliance. Personalized therapy, tailored to individual needs and comorbidities, further optimizes treatment outcomes. Long-term studies are needed to evaluate the sustained benefits of NIV on mortality, cardiovascular events, and quality of life. Additionally, pediatric applications of NIV show promise, but require further research to establish longterm safety and efficacy. This review underscores the transformative role of NIV in SRBD management, highlighting the need for ongoing research to refine and personalize these therapies for diverse patient populations.